Video

Dr. Jonasch on HIF-2α inhibitors in renal cell carcinoma

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Eric Jonasch, MD, discusses the potential of HIF-2α inhibitors, an emerging class of agents for the treatment of patients with renal cell carcinoma. Jonasch is a professor in the Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center.

      Related Content
      © 2025 MJH Life Sciences

      All rights reserved.